Daunorubicin

Generic name
Daunorubicin
Brand name
ATC Code
L01DB02
Compare …

Daunorubicin

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Oncological conditions
  • Intravenous
    • 0 years up to 18 years
      [2]

      • The dose and dosing frequency of cytostatic agents depend on the condition and are very much subject to new insights. Cytostatic drugs are mostly used in oncology and haematology in combinations. For this reason, please refer to the detailed treatment protocols.

        The following indicative dosages have been stated by the manufacturer:
        Monotherapy: 30-60 mg/m²/day for 3-5 days. The treatment can be repeated after 3-6 weeks.
        Combination therapy: Children: 25-50 mg/m²/day.
        Max cumulative dose:
        < 2 year: (or BSA < 0.5 m²): 10 mg/kg
        > 2 years: 300 mg/m².

        .

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Extravasation: apply cold compresses immediately, for at least 6 hours. Repeat this for 1 week, 4 times daily for 20 minutes. In serious cases, wound excision may be required.

The urine may be coloured red.

General cytostatic: a range of cytostatics can trigger hypersensitivity reactions. An emergency set (containing epinephrine, clemastine and hydrocortisone) should be present in the treatment room. The emergency set also contains specific antidotes.

Children are more susceptible to myocardial damage; they should be subject to long-term cardiological follow-up. Hypokalaemia also increases cardiotoxicity.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Anthracyclines and related substances
L01DB01
Other cytotoxic antibiotics
L01DC01

References

  1. Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
  2. Sanofi-Aventis Netherlands BV, SPC Cerubidine (RVG 05633), www.cbg-meb.nl, Geraadpleegd 26 jan 2012, http://db.cbg-meb.nl/IB-teksten/h05633.pdf

Changes

Therapeutic Drug Monitoring


Overdose